Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence→Stable
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $28.02 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD.
Kestra Medical Technologies is a commercial-stage medical device company that develops and leases the ASSURE WCD, an FDA-approved wearable cardioverter defibrillator for patients at elevated risk of sudden cardiac arrest. The company generated $59.8 million in revenue in the... Read more
Sell if holding. Analyst target reached at $28.02 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news boost analyst 0.35, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
Kestra Medical Technologies' ASSURE WCD, a wearable cardioverter defibrillator that received FDA premarket approval in July 2021, generates substantially all of the company's revenue, which reached $59.8 million for the fiscal year ended April 30, 2025, up 115% from $27.8 million a year earlier. Insurance coverage extended to over 285 million U.S. lives, approximately 90% of total available lives, as of April 30, 2025, spanning Medicare, Medicaid, and private payors.
Kestra generates revenue primarily by leasing the ASSURE WCD to patients on a month-to-month basis, billing Medicare, Medicaid, and private payors directly and collecting co-insurance and deductibles from patients. The device is fitted by a contracted network of over 300 patient specialists after being dispensed through Kestra's distribution network, then returned for reprocessing and reintroduction once a patient's prescribed wear period ends, an asset-recycling model built around a fleet of reusable devices. The company competes against a single incumbent WCD manufacturer that held the market exclusively for more than 20 years before the ASSURE WCD's 2021 approval, and management attributes historically low WCD penetration, just 14% of the eligible U.S. patient population in 2023, to that competitor's higher false-alarm rate and less comfortable garment design. Kestra had an accumulated deficit of $520.2 million as of April 30, 2025, following net losses of $113.8 million and $94.1 million in fiscal 2025 and fiscal 2024, respectively.
Show full overview
Kestra's business is structurally a single-product story: the 10-K states that revenue from the ASSURE WCD and its associated Cardiac Recovery System services will account for nearly all of the company's revenue for the foreseeable future, and management describes itself as 'highly dependent' on that one device. Should reimbursement rates decline, a safety signal emerge, or the incumbent competitor regain share, there is no second product line to absorb the impact — a concentration risk distinct from Kestra's early-stage losses, since it would persist even after the company reaches profitability.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted August 9, 2026.
Recent developments
updated 2026-08-15Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS This Guidewire Software Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday — benzinga Aug 10, 2026 positive
- NEWS JP Morgan Initiates Coverage On Kestra Medical Techs with Overweight Rating, Announces Price Target of $30 — benzinga Aug 10, 2026 positive
- NEWS Oppenheimer Initiates Coverage On Kestra Medical Techs with Perform Rating — benzinga Jul 21, 2026 positive
- NEWS BTIG Maintains Buy on Kestra Medical Techs, Raises Price Target to $32 — benzinga Jul 15, 2026 positive
- NEWS Kestra Medical Technologies Signs Five-Year, $200M Term Loan Financing — benzinga Jul 14, 2026 positive
Generated 2026-08-15T09:37:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $28.02 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.06. Score 5.4/10, moderate confidence.
Take-profit target: $32.22 (-6.9% upside). Prior stop was $26.06. Stop-loss: $26.06.
Concentration risk — Product: ASSURE WCD; Analyst target reached - limited upside remaining; Expensive valuation.
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -13.7). TrendMatrix value score: 2.4/10. Verdict: Sell.
13 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $30.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies is a commercial-stage medical device company that develops and leases the ASSURE WCD, an...
Kestra Medical Technologies is a commercial-stage medical device company that develops and leases the ASSURE WCD, an FDA-approved wearable cardioverter defibrillator for patients at elevated risk of sudden cardiac arrest. The company generated $59.8 million in revenue in the fiscal year ended April 30, 2025, up 115% year-over-year, primarily by billing Medicare, Medicaid, and private payors for device leases that account for substantially all of its revenue.